Skip to content
Medical Health Aged Care, Science

New gene discoveries improve diagnosis of inherited heart disease

Centenary Institute 2 mins read

Centenary Institute researchers have uncovered new genetic causes of inherited heart conditions, providing families with vital answers to guide treatment and prevention.

 

Inherited heart conditions affect more than one in every 200 Australians and are a major cause of illness and premature death.

 

The study, published in Genetics in Medicine, re-examined data from the Australian Genomics Cardiovascular Disorders Flagship, a national program that originally sequenced the genetic material of more than 500 Australians living with cardiomyopathy (heart muscle disease) or primary arrhythmia syndromes (abnormal heart rhythms).

 

The research team applied updated analysis methods, examined a broader range of heart-related genes and ran advanced laboratory tests to check the impact of uncertain DNA variations in the genomic dataset. With this deeper investigation, they were able to give an extra 4% of participants a confirmed genetic diagnosis that earlier testing had missed.

 

“Each additional diagnosis has a direct and tangible impact,” said Associate Professor Richard Bagnall, Head of the Centre for Cardiovascular Research at the Centenary Institute and senior author of the study.

 

“It explains why a person developed heart disease, informs their treatment and can guide genetic screening for relatives who may also be at risk.”

 

The study also confirmed a new disease-causing gene (TBX20) for cardiomyopathy that had previously been omitted in standard testing.

 

“These results show us that the genetic basis of heart disease is broader and more complex than we once thought,” said Yuchen Chang, PhD candidate at the University of Sydney and the Centenary Institute, and first author of the study.

 

“By continually updating gene panels (checklists of genes linked to specific heart conditions) and validating uncertain results in the laboratory, we can improve diagnosis rates and deepen our understanding of these conditions.”

 

The researchers say that re-analysing genomic data with the latest tools and knowledge will continue to improve genetic diagnosis for inherited heart conditions. This means more families can receive timely answers, clinicians can tailor care more effectively and new discoveries can be more quickly put into practice to benefit patients.

 

[ENDS]

 

Publication: Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses

https://www.sciencedirect.com/science/article/pii/S1098360025002734


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

For more information about the Centenary Institute, visit centenary.org.au


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

More from this category

  • Medical Health Aged Care
  • 21/01/2026
  • 06:10
Amoeba

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Chassieu, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm -Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, recaps its recent participation in SIVAL (International Exhibition of Plant Production Techniques) in Angers (France). During this leading European and global event for the crop industry, Amoéba won the gold medal in the SIVAL Innovation 2026 Competition for its biocontrol solution and announced, together with its partner Koppert, the commercial launch in 2026 of its biocontrol solution for treating vineyards and vegetable crops as…

  • Medical Health Aged Care
  • 21/01/2026
  • 00:41
Crown Bioscience

Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities

SAN DIEGO–BUSINESS WIRE– Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory…

  • Contains:
  • Medical Health Aged Care
  • 20/01/2026
  • 10:00
Monash University

Monash University researcher appointed to the board of the Asthma Council

The National Asthma Council Australia (NAC) has announced the appointment of Pharmaceutical Society of Australia (PSA) nominee Dr Amanda Cross to the board. Dr Cross is a clinical pharmacist and Senior Research Fellow at Monash University's Centre for Medicine Use and Safety, within the Monash Institute of Pharmaceutical Sciences (MIPS). Her work focuses on medicine safety and quality use of medicines for older adults. She is particularly interested in the role of healthcare professionals working as knowledge brokers to support the uptake of research evidence and guidelines into clinical practice. Evidence-to-practice gaps are a major barrier to avoiding medication-related harm.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.